Rocket Lab: A Buy Ahead Of SpaceX IPO

Rocket Lab guided Q1 revenue to $185 million-$200 million and cited GAAP margins of 34%-36%, alongside improving non-GAAP margins. FY25 backlog reached $1.85 billion, with 74% tied to Space Systems, supporting multi-year revenue visibility and an expected 37% FY26 conversion. Launch cadence gains also reduced cost per launch to $4.8 million from $5.7 million, indicating improving scale-driven fixed-cost leverage.

Analysis

The key underappreciated shift is that this is no longer a pure launch-rate story; it is increasingly a software-like backlog conversion business with defense-adjacent visibility. A backlog dominated by Space Systems should compress earnings volatility because it converts through longer procurement cycles and tends to be stickier than launch bookings, which means the market may be underpricing the quality of future revenue, not just the quantity.

The margin bridge matters more than top-line guidance. A lower cost per launch implies that each incremental mission is now carrying materially more contribution, so the next inflection is likely to come from operating leverage rather than revenue beat size. That typically rerates as investors move from valuing the company on near-term burn to valuing it on forward free cash flow and backlog duration, but only if execution remains clean over the next 2-3 quarters.

The biggest second-order winner is probably the supply chain and subsystem ecosystem tied to spacecraft integration, where higher cadence can pull through recurring demand without requiring equivalent capital intensity. The main losers are smaller launch competitors that need premium pricing to offset fixed costs; if this cost curve persists, it becomes harder for subscale players to compete on both price and reliability, especially in defense procurement where schedule confidence is increasingly valuable.

Consensus risk is that the market may extrapolate too aggressively from one quarter of improved efficiency. The real test is whether the launch cadence and margin profile can hold through a disruption-free year; any slip in manifest timing, customer acceptance, or program execution would hit both the growth narrative and the multiple. Over 6-18 months, the stock is vulnerable to "good but not better" fatigue if backlog conversion stays around expectations rather than accelerating.

Key Decisions for Investors

• Build a starter long in RKLB on any 5-8% post-guidance pullback; thesis is backlog quality plus fixed-cost leverage, with 6-12 month upside if launch costs remain near the new run-rate.
• Use call spreads instead of outright equity for a 3-6 month view: buy RKLB calls and sell higher strikes to express upside from rerating while limiting downside if execution stalls.
• Pair trade: long RKLB / short a subscale aerospace or launch peer basket where pricing power is weaker; the trade benefits if the market rewards durable backlog and penalizes firms with inferior unit economics.
• If already long, trim only on signs of cadence slippage, not on headline multiple expansion; the risk/reward is favorable as long as the company continues to show margin expansion over the next 2 quarters.
• Watch for contract wins tied to defense payloads and Space Systems conversions over the next 1-2 quarters; those would be the cleanest catalysts for a further re-rate.